BPC-157 vs TB-500: Local vs Systemic Healing

BPC-157 vs TB-500 comes down to local-and-systemic versus systemic-only. BPC-157 is the better-researched all-rounder studied for tendons, joints and gut, active both at the injection site and through the bloodstream, and orally usable. TB-500 is the systemic-migration specialist studied for muscle and whole-body repair, injection only, with a much thinner evidence base.

The two come up together so often that researchers treat them as a pair, the "Wolverine stack". They are both healing peptides, both studied for building new blood vessels into damaged tissue, and the literature on each describes complementary mechanisms. But they are not the same molecule, and they are not interchangeable.

Primogen stocks both, and both are sold as research compounds only. Here is how they actually differ.

BPC-157 vs TB-500: what is the difference at a glance?

BPC-157 is the local-and-systemic, orally active, far-better-researched peptide for tendons, joints and gut; TB-500 is the injection-only, systemic-migration peptide studied for muscle and whole-body repair, on a thinner evidence base. The table below lays the two side by side.

How do BPC-157 and TB-500 work differently?

They act through different mechanisms in the research: BPC-157 is studied for improving local blood supply and tissue responsiveness at and around an injury site, while TB-500 is studied for mobilising cells to migrate toward damaged tissue from across the body. That mechanistic split is why the literature treats them as complementary rather than redundant.

BPC-157 is a synthetic copy of a fragment of a protective protein found in gastric juice, which is a clue to two of its studied properties: in animal models it is reported to protect and repair the gut lining, and it is stable enough to survive oral administration. In damaged tissue it is reported to drive angiogenesis, the growth of new blood vessels, which is how nutrients and repair signals reach an injury that has poor blood supply of its own (tendons and ligaments are notoriously badly supplied). In tendon fibroblasts it has also been reported to upregulate growth hormone receptors (Chang et al. 2014), which in vitro made those cells more responsive to growth hormone signalling. Across the wound-healing literature it is described as acting locally, systemically once dispersed through the bloodstream, and through the gut wall when given orally (Sikiric et al. 2021).

TB-500 comes at healing from a different direction in the research. It is a synthetic version of an active region of Thymosin Beta-4, a protein involved in coordinating repair. Its main described action is binding up actin (a structural protein inside cells), which is associated with freeing those cells to migrate toward damaged tissue. A useful mental model from the literature: BPC-157 is studied for improving the building site, TB-500 for getting the workers to the site faster from all over the body. That systemic, migration-driving action is why it is studied in the context of muscle injury and whole-body recovery rather than one specific tendon.

In short: in the research, both are described as systemic once injected. BPC-157 adds precise local action and gut effects on top, and is far better researched; TB-500 is the systemic-migration specialist.

What does the research on BPC-157 vs TB-500 actually say?

BPC-157 is the better-evidenced of the two by a wide margin: it sits on 180-plus animal studies plus a growing handful of small human reports, whereas TB-500 rests on only around five studies of the specific fragment. Neither has a large randomised human trial, so both should be read as research compounds, but the depth gap between them is real.

BPC-157. It has been through 180-plus animal studies and a small number of early human reports. In one small retrospective case series of intra-articular BPC-157 (injected directly into the joint space) for knee pain, the authors reported that around 92% of patients given BPC-157 on its own showed significant improvement in knee pain, on follow-up running from six months to a year after injection (Lee & Padgett 2021). There are also early human reports involving gut conditions. A 2025 review weighing the upside against the unknowns frames it as "regeneration or risk?", which captures the state of the evidence honestly (McGuire et al. 2025). None of this is a large randomised trial, so it is not bulletproof, but for a research peptide it is unusually well documented.

TB-500. The evidence here is much thinner. There are only around five studies on the specific fragment referred to as TB-500, versus well over a thousand on the parent Thymosin Beta-4 protein. A lot of what gets claimed for TB-500 is really extrapolated from research on the full protein, which is not the same molecule. Worth knowing before you assume the two are equally proven.

BPC-157 or TB-500: which should you choose?

For most research interests the verdict is "both", because the two mechanisms described in the literature are complementary rather than overlapping: BPC-157 is studied for local blood supply and tissue responsiveness, TB-500 for bringing repair cells in. That is why the combination (often sold as a BPC plus TB blend) is the default pairing. If you are choosing one, the split below maps each to who it suits.

Who should choose BPC-157. The researcher focused on a specific tendon, ligament, joint or gut model, who wants local-and-systemic action, an oral option, and the deeper evidence base. Not a fit if the question is whole-body or muscle-wide recovery, where a single localised peptide is the wrong tool, or if injection-free use is the only requirement and you have no need for its other properties.

Who should choose TB-500. The researcher focused on systemic, muscular or whole-body migration models where a single-site peptide is not the point. Not a fit if you want the better-documented compound, an oral route, or a gut-focused model, where the TB-500 evidence base is thin or absent.

Who should run both. Anyone modelling broad, multi-tissue recovery rather than one isolated site. Not a fit if budget is tight and the interest is genuinely one specific tendon or gut model, in which case the single relevant peptide is the leaner choice.

Primogen stocks both on their own and as a ready-made BPC plus TB blend, so the pair runs from a single vial. They also anchor two broader healing blends: GLOW (BPC-157, TB-500 and GHK-Cu, the copper peptide) and KLOW (those three plus KPV). For multi-angle research rather than one specific model, a blend covers several compounds from a single reconstitution. There is more on the blends, and the myths about them, in the GLOW and KLOW blends guide.

What are the typical research doses and cycles for BPC-157 and TB-500?

The protocols quoted in the research literature differ in both amount and frequency: BPC-157 is generally cited around 250-500 mcg per day (some protocols go to 1000 mcg) on roughly 4-8 week cycles, while TB-500 is cited with a loading phase of around 2-5 mg per week split across doses, then a lower maintenance amount, on roughly 8-week cycles. Both are short-lived in the blood, so the cited schedules favour steady, repeated exposure.

• BPC-157: typically 250-500 mcg per day, administered subcutaneously near the site for a local model, or orally for gut models. Cycles usually run 4-8 weeks.
• TB-500: usually a loading phase of around 2-5 mg per week (split into a couple of doses), then a lower maintenance dose. Cycles usually run about 8 weeks.

A worked reconstitution example. Take a 5 mg BPC-157 vial reconstituted with 2 mL of bacteriostatic water. That gives 2500 mcg per mL, or 25 mcg per unit on a standard U-100 insulin syringe (100 units per mL). A 250 mcg measure is therefore 10 units, and a 500 mcg measure is 20 units on that syringe. Change the water volume and the units-per-dose change proportionally, so the how to reconstitute and dose guide walks through the arithmetic for any vial size.

A general rule for both protocols: cycle them, do not run them continuously. There is no human safety data beyond around a year, so the common research convention of several weeks on followed by several weeks off is the default in the literature. The BPC-157 deep-dive goes into the full protocols.

What are the safety considerations with BPC-157 and TB-500?

Neither is a "free" compound, and the same two cautions apply to both: a theoretical angiogenesis concern and a real source-quality risk. Both are research compounds with no large human safety dataset, which is the single most important framing here.

• Angiogenesis is double-edged. The new-blood-vessel growth described in the healing literature is, in theory, the same process tumours use, so the proliferation that researchers study for repair is also a flagged concern in any cancer context. A 2025 review explicitly weighs this regeneration-versus-risk tension (McGuire et al. 2025). It is a theoretical concern rather than a documented event, but worth understanding before any use.
• Source quality is a real risk, not a marketing line. Poorly made "research only" peptides can carry LPS (endotoxin) contamination, which is pro-inflammatory and can accumulate. This is exactly why the certificate of analysis on what you buy matters, and why you should know how to read one. We wrote a plain-English guide on how to read a COA.

One more honest limit: nothing in this literature suggests a peptide can reattach a fully torn tendon or resolve a serious structural injury. These are research materials, not a substitute for a proper diagnosis. A full rupture is a matter for a doctor, not a vial.

Both are also on the WADA prohibited list, so they are off-limits for tested athletes.